Out of 223 evaluable patients, 78% had a complete response, which, in this case, indicates that patients had no cancer left in the bladder according to an internal visual analysis called cystoscopy ...

The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to detalimogene voraplasmid for the treatment of high-risk, Bacillus Calmette-Guérin ...

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive ...

The Food and Drug Administration (FDA) has approved Zusduri (mitomycin intravesical solution) for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC).

The FDA approved mitomycin intravesical solution (Zusduri) for patients with recurrent low-grade intermediate risk non–muscle-invasive bladder cancer (NMIBC).

Urine cytology is a test to screen a patient’s urine for cancer cells. This is one of many tools used to diagnose cancer of the bladder or urinary tract. A urine cytology test is used together with ...

The trial’s primary end point was complete response (CR), defined as no disease in the bladder as determined by cystoscopy and urine cytology along with a biopsy if necessary, at 3 months, and ...

A medical check-up begins once a patient walks into a doctor’s office. There are various things the doctors take note of, and ...

HCRN GU 16-257 was a phase II trial of cisplatin-eligible cT2-T4aN0M0 urothelial bladder cancer patients who received 4 cycles of gemcitabine, cisplatin, plus nivolumab (RETAIN – chemotherapy alone) ...

Innovative new technology could soon mean that screening for cervical cancer won’t be as uncomfortable as a Pap test, ...